Apoptotic study in Graves disease treated with thyroid arterial embolization.
OBJECTIVE
To investigate apoptosis in the thyroid of Graves disease (GD) induced by thyroid arterial embolization.


METHODS
Forty one patients with clinically and laboratorily ascertained GD were treated with thyroid arterial embolization and followed up for 3-54 months following embolization. Prior to embolization and at 1, 3, 6, 12 and 36 months following embolization, thyroid autoimmunue antibodies were tested respectively, including thyroid stimulating antibody (TSAb), thyroglobulin antibody (TGAb) and thyroid microsomal antibody (TMAb). Thyroid biopsy was performed under the guidance of computed tomography for immunohistochemistry examination using semi-quantity analysis.


RESULTS
The positive staining of Fas and FasL was mostly in the cytoplasma and cell membrane, the positive expression of Bax was mainly in the cytoplasma, and no positive expression of P53 was detected in the thyroid cells before embolization. After arterial embolziation, the positive cell number and staining degree of these genes were both greater than before embolization.


CONCLUSIONS
The treatment method of thyroid arterial embolization can effectively enhance the positive expression of pro-apoptotic genes of Fas, FasL, Bax, Bcl-2 and P53 in GD thyroid, thus promoting apoptosis of GD thyroid and helping restore the thyroid size and function to normal conditions.
Zhao
Wei
W
Medical Imaging Center, First Affiliated Hospital, Kunming Medical College, Kunmin, Yunnan Province, China.
Gao
Bu Lang
BL
Yi
Gen Fa
GF
Jin
Cang Zheng
CZ
Yang
Hui Ying
HY
Shen
Li Juan
LJ
Tian
Min
M
Yu
Yong Zhong
YZ
Li
Hong
H
Song
Dian Ping
DP
D000293:Adolescent; D000328:Adult; D017209:Apoptosis / Q000276:immunology*; D001158:Arteries; D001323:Autoantibodies / Q000097:blood; D004621:Embolization, Therapeutic; D053222:Fas Ligand Protein / Q000096:biosynthesis; D005260:Female; D015870:Gene Expression; D006111:Graves Disease / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D013961:Thyroid Gland / Q000098:blood supply / Q000276:immunology*; D013963:Thyroid Hormones / Q000097:blood; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis; D051028:bcl-2-Associated X Protein / Q000096:biosynthesis; D019014:fas Receptor / Q000096:biosynthesis
D001323:Autoantibodies; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D019253:Proto-Oncogene Proteins c-bcl-2; D013963:Thyroid Hormones; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; D019014:fas Receptor